Improved Outcomes at Late Follow-up (LFU) with Plazomicin Compared with Meropenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) in the EPIC Study

• Published in: Open forum infectious diseases 2017-10, Vol.4 (suppl_1), p.S533-S534
• Main Authors: Golan, Yoav, Cloutier, Daniel J, Komirenko, Allison S, Cebrik, Deborah S, Keepers, Tiffany R, Krause, Kevin M, Connolly, Lynn E, Wagenlehner, Florian M.E
• Format: Article
• Language: English
• ISSN: 2328-8957; 2328-8957
• DOI: 10.1093/ofid/ofx163.1389

Abstract Background The urinary tract is a common source for multidrug-resistant (MDR) gram-negative infections. The recurrent nature of cUTI leads to frequent antibiotic exposure with attendant potential for resistance development. Plazomicin, a next-generation aminoglycoside with in vitro activity against MDR Enterobacteriaceae, demonstrated non-inferior efficacy to meropenem for treatment of cUTI, including AP, and significantly higher microbiological eradication rates at the test-of-cure (TOC) visit in the EPIC study (Cloutier DJ, et al. ASM 2017). Here, we present the impact of these findings on subsequent microbiological and clinical outcomes at the LFU visit. Methods In this randomized, double-blind study, hospitalized patients with cUTI or AP were randomized to intravenous (IV) plazomicin (15 mg/kg q24h) or IV meropenem (1 g q8h), with optional oral step down, for a total of 7–10 days of therapy. Composite cure (combined microbiological eradication and clinical cure), microbiological eradication (reduction of baseline pathogen to